Immunization

VAERS was designed to collect reports of symptoms, diagnoses, hospital admissions, and deaths after vaccination for postmarket safety signals.

Ixchiq was approved through the FDA Accelerated Approval pathway.

Mebella is another weapon in the global fight to eradicate these diseases.

In a recent Morbidity and Mortality Weekly Report (MMWR), the results of a study showed 63% of those who died from HAV had at least 1 documented preexisting indication for vaccination.

The FDA is advising health care professionals who administer the vaccine to make sure the correct volume of the vaccine is withdrawn from the vial and the correct dose is administered to the patient.

Care home staff play a role in transmission to elderly residents by bringing flu in from their communities, especially in winter. Vaccination can combat this risk, but not all care workers get flu shots.

A new study adds to previous research that has found religious and political correlations between vaccine beliefs and hesitancy, which have geographical links.

Explore the latest in COVID-19 management, where essential education is provided on key developments, crucial updates, expert guidance, and real-world scenarios that will enhance understanding of best practices. Learn more from a simulated pharmacist/patient encounter, where practical insights are offered on how to incorporate FDA and CDC recommendations for patients with COVID-19.

Learn about best practices in identifying high-risk patients for COVID-19 complications. This video empowers healthcare providers with the knowledge to proactively address and manage complex COVID-19 cases effectively. Stay ahead in the ever-evolving landscape of healthcare by unlocking key strategies that enhance patient outcomes and contribute to the collective effort in preventing COVID-19 complications.

Empower your practice with the tools to combat vaccine hesitancy. This informative video tackles the nuanced challenges of addressing vaccine hesitancy, offering healthcare providers valuable strategies to engage with patients and build trust in vaccination. Enhance your communication skills, navigate common concerns, and contribute to the broader mission of achieving widespread immunity against COVID-19 with this video.

Stephen L. Foster, PharmD, FAPhA, FNAP, discussed the new vaccine and RSV prevalence at the National Community Pharmacists Association 2023 Convention and Expo.

Research findings may support further COVID-19 vaccination in children.

Jean-Venable R. Goode, PharmD, director of the PGY1 Community Based Residency Program at Virginia Commonwealth University, discussed the new vaccine guidelines from ACIP.

Based on data from an ongoing clinical trial and other studies, the R21 vaccine has been shown to have a high degree of efficacy when administered just before the high transmission season, with data showing a 75% reduction in cases of malaria in the 12 months following the 3-dose series.

During a podcast hosted by Permanente Medicine, Sandra Fryhofer, MD, chair-elect of the Board of Trustees for the American Medical Association and a liaison to the CDC’s Advisory Committee on Immunization Practices, discussed the importance of vaccines for the fall and winter seasons.

Moderna plans to begin a phase 3 trial of the combination vaccine this year.

The monovalent vaccine offers a protein-based non-mRNA option.

Vaccines were tested against various strains of the SARS-CoV-2 virus.

By offering vaccines year-round instead of only during the typical flu season, community pharmacies can maximize profits and help patients live healthier lives.

Katalin Karikó, PhD, and Drew Weissman, MD, PhD, were cited "for their discoveries concerning nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19."

Standout updates include a relaxed recommendation for patients with a history of egg allergies, and that all available influenza vaccines for the 2023 to 2023 flu season are quadrivalent.

The mRNA-1010 vaccine generated a powerful response against 4 influenza virus strains compared to traditional flu shots.

Patients who were vaccinated and reinfected showed symptoms of few lesions, little mucosal disease, and minimal analgesia requirements.

Vaxart’s VP1-based bivalent oral tablet vaccine was developed to target the norovirus GI.1 Norwalk and GII.4 Sydney strains, which are the predominant strains affecting humans.

Previous clinical data has shown that the vaccine also generates a strong response to the EG.5 and FL.1.5.1 variants.

According to the Centers for Disease Control and Prevention, tens of thousands of HPV-related cancer diagnoses were given per year from 2015 to 2019.

Study authors conclude that all children should be up to date with recommended COVID-19 vaccines and initiate the vaccination process immediately when products become available.

Resources with pertinent information are essential in motivating individuals to comply with vaccine recommendations.

The CDC and WHO are currently tracking several variants that are driving the majority of new cases around the world.